HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia
Public ClinicalTrials.gov record NCT04424290. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A First-in Human Trial to Study Safety and Tolerability of Single Rising Intravitreal dOses (Open Label, Non-randomized, Uncontrolled) and in Addition the Early Biological Response of Multiple intravitReal Dosing (Single-masked, raNdomized, Sham-controlled) of BI 764524 in panretinaL Photocoagulation (PRP) Treated proLiferative Diabetic Retinopathy (PDR) Patients With Diabetic Macular Ischemia (DMI) - the HORNBILL Study
Study identification
- NCT ID
- NCT04424290
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 45 participants
Conditions and interventions
Conditions
Interventions
- BI 764524 Drug
- Sham control of BI 764524 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 11, 2020
- Primary completion
- Apr 27, 2023
- Completion
- Apr 27, 2023
- Last update posted
- May 21, 2024
2020 – 2023
United States locations
- U.S. sites
- 13
- U.S. states
- 8
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Trinity Research | Dothan | Alabama | 36301 | — |
| Retina-Vitreous Associates Medical Group | Beverly Hills | California | 90211 | — |
| Stanford University Medical Center | Palo Alto | California | 94303 | — |
| Florida Retina Institute | Orlando | Florida | 32806 | — |
| Raj K. Maturi, MD PC | Carmel | Indiana | 46290 | — |
| Joslin Diabetes Center | Boston | Massachusetts | 02115 | — |
| Long Island Vitreoretinal Consultants | Great Neck | New York | 11021 | — |
| New York Eye and Ear Infirmary of Mount Sinai | New York | New York | 10003 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Austin Research Center for Retina, PLLC | Austin | Texas | 78705 | — |
| Retina Consultants of Texas | Bellaire | Texas | 77401 | — |
| Valley Retina Institute, PA | McAllen | Texas | 78503 | — |
| Retina Consultants of Texas | The Woodlands | Texas | 77384 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04424290, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 21, 2024 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04424290 live on ClinicalTrials.gov.